{
  "pmcid": "12160125",
  "sha256": "455aea6ef1c4f76e9c3d91903bbe13153dd06b098be6144a1944618305bef4bd",
  "timestamp_utc": "2025-11-09T22:17:20.051152+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.920469483568077,
    "reading_ease": 30.819327073552444,
    "word_count": 213
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of a Nomogram for Predicting Spread Through Air Spaces in Stage IA Lung Adenocarcinoma"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "A retrospective analysis was conducted on 1,375 patients with stage IA LUAD at Sun Yat-sen University Cancer Center."
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to develop a preoperative prediction model for Spread Through Air Spaces (STAS) in stage IA lung adenocarcinoma (LUAD) to guide surgical decision-making."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "The study was conducted between December 2020 and October 2022."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Irregular nodule shape (OR = 1.817, 95% CI: 1.106–2.986, p = 0.018), irregular margin (OR = 2.050, 95% CI: 1.218–3.449, p = 0.007), lobulation (OR = 2.235, 95% CI: 1.336–3.739, p = 0.002), and vascular convergence (OR = 5.032, 95% CI: 2.050–12.349, p < 0.001) were significantly associated with increased STAS risk."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not applicable."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 10,
    "max_score": 25
  }
}